

Consolidated income statement for the year ended 31 December 2014¹

x € million	Notes	Continuing operations		Discontinued	Total
		Before exceptional items	Exceptional items (note 6)	operations	
				Total	
Net sales	4	7,051	-	7,051	9,283
Cost of sales	4	(4,803)	(1)	(4,804)	(7,165)
Gross margin		2,248	(1)	2,247	(129)
Marketing and sales		(921)	-	(921)	(1,021)
Research and development		(304)	-	(304)	(323)
General and administrative		(451)	(35)	(486)	(519)
Other operating income		53	10	63	114
Other operating expense		(38)	(34)	(72)	(79)
	4	(1,661)	(59)	(1,720)	(1,828)
Operating profit		587	(60)	527	(237)
Interest costs	5	(109)	(7)	(116)	(132)
Other financial income and expense	5	7	-	7	7
Profit before income tax expense		485	(67)	418	165
Income tax expense	7	(84)	11	(73)	(7)
Share of the profit of associates and joint ventures		8	(66)	(58)	(59)
Profit for the year		409	(122)	287	(99)
Reclassification of the net result from activities disposed of		-	(196)	(196)	-
Total		409	(318)	91	8 ²
Of which:					
- Profit attributable to non-controlling interests	18	(5)	(37)	(42)	(46)
- Net profit attributable to equity holders of Koninklijke DSM N.V.		414	(281)	133	145
Net profit attributable to equity holders of Koninklijke DSM N.V.		414	(281)	133	145
Dividend on cumulative preference shares		(10)	-	(10)	(10)
Net profit available to holders of ordinary shares		404	(281)	123	135
Earnings per share (in €)	17				
- Basic				1.63	0.78
- Diluted				1.63	0.78

¹ The split in results over continuing and discontinued operations in 2014 has been restated due to the disposal of the caprolactam, acrylonitrile and composite resins businesses (now included under discontinued operations). See also note 1 General information and note 2 Change in the scope of the consolidation.

² Excluding exceptional items.